معرفی
Michael Fischbach is the Liu (Liao) Family Professor of Bioengineering at Stanford University, an Institute Scholar of Stanford ChEM-H, and director of the Stanford Microbiome Therapies Initiative. His research focuses on microbiome-host interactions, antibiotic discovery, and bacterial pathogenesis mechanisms.
Education: PhD in Chemistry from Harvard University (2007), studying iron acquisition in bacterial pathogens and antibiotic biosynthesis. Postdoctoral work at Massachusetts General Hospital before joining UCSF in 2009, later moving to Stanford in 2017.
Research interests include understanding how microbes communicate with hosts, developing therapies from microbial metabolites, and leveraging chemical biology approaches to combat infectious diseases.
Awards: NIH Pioneer & New Innovator Awards, Packard Fellowship, HHMI-Simons Scholars Award, and the Vannevar Bush Faculty Fellowship. Active in translational medicine through co-founding companies like Kelonia and Revolution Medicines.
Labs/Teams: Leads the Fischbach Lab at Stanford, focused on microbiome-driven therapies and host-pathogen interactions. Serves on scientific advisory boards for Chan Zuckerberg Initiative, NGM Biopharmaceuticals, and TCG Labs/Soleil Labs.
